With a market capitalisation of nearly A$100m, Actinogen Medical (ASX: ACW) is an innovative clinical-stage Australian biotech company pioneering the development of Xanamem, a novel therapeutic drug candidate targeting Alzheimer’s disease and major depressive disorder. Xanamem, also known as emestedastat, is a first-in-class, brain-penetrant cortisol inhibitor, and it is the only molecule of its kind in advanced-stage clinical trials for Alzheimer’s.

There are five compelling reasons why Actinogen Medical represents an attractive investment opportunity.

• Firstly, Actinogen Medical’s Xanamem stands out in the complex and crowded Alzheimer’s drug development landscape. Unlike other treatments that largely focus on amyloid plaques or tau protein, Xanamem targets excessive cortisol production in the brain – a mechanism strongly linked to cognitive decline and a unique approach among clinical-stage Alzheimer’s drug candidates. Xanamem is an oral medication conveniently dosed once daily and has already demonstrated a favourable safety profile in over 400 patients and volunteers. With Alzheimer’s disease expected to affect nearly 14 million Americans by 2060 and the current leading anti-amyloid treatments offering only limited efficacy (associated with potentially serious side effects and requiring invasive intravenous administration), Xanamem could alter the treatment paradigm. Further, given the drug’s excellent tolerability to date, Xanamem has the potential to be used both as a standalone treatment or as an adjunctive therapy.
• Secondly, Actinogen Medical is currently running its Phase 2b/3 XanaMIA trial in biomarker-confirmed Alzheimer’s disease, specifically in patients with elevated pTau protein in the blood. This trial builds on the positive efficacy data from the earlier XanADu trial, where Xanamem showed a clinically significant 0.6 mean difference on the Clinical Dementia Rating – Sum of Boxes scale among Alzheimer’s patients with elevated blood pTau, representing a 60% relative reduction in disease progression. By enrolling over 220 patients from this well-defined and responsive population, the XanaMIA trial is designed to replicate and extend the positive efficacy signal observed in XanADU. Interim results are expected in late 2025, with final results in the second half of 2026. These milestones are major catalysts that could drive a significant rerating for the stock and potentially lead to value realisation through licensing transactions.
• Thirdly, in addition to Alzheimer’s, the company is also advancing Xanamem in major depressive disorder, with positive Phase 2a efficacy data already reported in August 2024. Discussions with regulators for pivotal studies in depression are underway. Xanamem could also have utility in other neuropsychiatric conditions like Fragile X syndrome and bipolar disorder. Altogether, these neuropsychiatric indications all expand the drug’s potential, and Actinogen Medical is seeking partnerships and/or non-dilutive funding before advancing new clinical trials in areas outside of Alzheimer’s disease. Such arrangements would help de-risk future development costs, while still allowing Actinogen Medical to crystallise the full commercial potential of Xanamem.
• Fourthly, Actinogen Medical benefits from Australian R&D tax credits, covering up to 48.5% of its eligible expenses. This significantly reduces its net development costs and enhances its competitive position for future clinical development. Further, the company has already finalised the tablet formulation of Xanamem and begun scaling up to commercial-scale manufacturing through its contract manufacturing partner, ensuring its readiness for commercial-scale production and to potentially engage in licensing or partnership transactions.
• Finally, the company’s multi-functional and experienced leadership team and its board of directors have been successful in taking and advancing new products from early-stage development stages towards regulatory approval and market preparations, launch and/or company sale or exit. As a development-stage company, Actinogen Medical will likely need additional capital to fund Xanamem’s future clinical development, particularly for a second Phase 3 study in Alzheimer’s. The company has mitigated this risk somewhat as it expects its A$23m cash position at the end of 2024 to be sufficient for Actinogen Medical to fund and reach completion of the current XanaMIA phase 2b/3 trial. This potentially pivotal milestone could be transformative for the company’s valuation should it confirm positive efficacy in biomarker-positive Alzheimer’s patients. Moreover, Actinogen Medical and its management team have consistently succeeded in seeking and completing capital raises, while consistently maintaining a robust cash runway. In addition, the company may also seek non-dilutive funding activities including licensing, partnerships and/or additional funding from government agencies and patient advocacy groups.

Published 10th April 2025